Discontinued — last reported Q4 '25

Operating

D&A

Amgen D&A decreased by 1.4% to $1.12B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 19.5%, from $1.39B to $1.12B. Over 4 years (FY 2021 to FY 2025), D&A shows an upward trend with a 11.0% CAGR.

Analysis

StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ4 2025

How to read this metric

Higher levels typically reflect significant historical capital expenditures or acquisitions that are now being expensed over time.

Detailed definition

This metric represents the non-cash accounting charges used to allocate the cost of tangible assets and intangible asset...

Peer comparison

Capital-intensive hardware manufacturers generally show higher D&A relative to revenue than pure-play software companies.

Metric ID: depreciation_and_amortization_cf

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$855.00M$850.00M$852.00M$841.00M$828.00M$837.00M$911.00M$900.00M$896.00M$895.00M$1.38B$1.40B$1.40B$1.40B$1.40B$1.39B$1.34B$1.31B$1.13B$1.12B
QoQ Change-0.6%+0.2%-1.3%-1.5%+1.1%+8.8%-1.2%-0.4%-0.1%+54.2%+1.4%+0.1%-0.3%+0.1%-0.7%-3.3%-2.5%-13.4%-1.4%
YoY Change-3.2%-1.5%+6.9%+7.0%+8.2%+6.9%+51.5%+55.4%+56.3%+56.0%+1.2%-0.9%-4.2%-6.4%-19.0%-19.5%
Range$828.00M$1.40B
CAGR+5.8%
Avg YoY Growth+12.2%
Median YoY Growth+4.1%
Current Streak5 quarters decline

Frequently Asked Questions

What is Amgen's d&a?
Amgen (AMGN) reported d&a of $1.12B in Q1 2026.
How has Amgen's d&a changed year-over-year?
Amgen's d&a decreased by 19.5% year-over-year, from $1.39B to $1.12B.
What is the long-term trend for Amgen's d&a?
Over 4 years (2021 to 2025), Amgen's d&a has grown at a 11.0% compound annual growth rate (CAGR), from $3.40B to $5.17B.
What does d&a mean?
The accounting process of spreading the cost of physical and intangible assets over time.